# UK 15-Year TOP Poster Presented at EAN 2023
Keywords: TYSABRI, multiple sclerosis, natalizumab, observational study, relapsing-remitting multiple sclerosis, safety, effectiveness, adverse events, disability progression, relapse rate

> This page presents findings from a 15-year observational study on the safety and effectiveness of natalizumab (TYSABRI) in treating relapsing-remitting multiple sclerosis (RRMS), highlighting long-term outcomes, relapse rates, and disability progression.

## Details
- [Objective](#): Interim analysis of safety and effectiveness data for RRMS patients treated with natalizumab over 15 years.
- [Conclusions](#): Reinforces consistent effectiveness and established safety profile of natalizumab, with significant reductions in relapse rates and stable disability outcomes.
- [Methods](#): Details of the study design, including data collection, statistical analysis, and patient enrollment criteria.
- [Results](#): Key findings on patient outcomes, including relapse rates, disability progression, and safety events.
- [Safety](#): Overview of adverse events, including serious adverse events, opportunistic infections, and malignancies reported during the study.